Advertisement

Tumor Biology

, Volume 37, Issue 8, pp 11249–11257 | Cite as

The value of serum RASSF10 hypermethylation as a diagnostic and prognostic tool for gastric cancer

  • Wan-Jiang Xue
  • Ying Feng
  • Fei Wang
  • Peng Li
  • Yi-Fei Liu
  • Yi-Bing Guo
  • Zhi-Wei Wang
  • Qin-Sheng Mao
Original Article

Abstract

The tumor-suppressing role of Ras-association domain family 10 (RASSF10) has been described in several types of cancers. Here, we evaluated the potential use of the hypermethylation status of the RASSF10 promoter in serum as a new diagnostic and prognostic tool in gastric cancer (GC). We used bisulfite sequencing polymerase chain reaction to examine RASSF10 methylation levels in serum and/or tumor samples from 82 GC, 45 chronic atrophic gastritis (CAG), and 50 healthy control patients. In the serum of GC patients, the median level of RASSF10 methylation was higher at 47.84 % than those in the serum of CAG and healthy control patients at 11.89 and 11.35 %, respectively. The median level of RASSF10 methylation in GC tumor tissue was similarly high at 62.70 %. Furthermore, RASSF10 methylation levels were highly correlated between paired serum and tumor samples from GC patients. We performed receiver-operating characteristic curve analyses to verify that serum RASSF10 methylation levels could effectively distinguish GC from control patients. Moreover, multivariate analyses showed that high serum RASSF10 methylation levels in GC patients were associated with large tumors, lymph node metastasis, and high carcinoembryonic antigen (CEA) levels. Survival analyses showed that GC patients with high serum RASSF10 methylation levels had shorter overall and disease-free survival after D2 lymphadenectomy than those with low levels. High serum RASSF10 methylation levels were also an independent predictor of tumor recurrence and GC patient survival. In conclusion, serum RASSF10 promoter methylation levels can serve as a valuable indicator for the diagnosis and prognosis of GC in the clinic.

Keywords

RASSF10 Gastric cancer Serum Hypermethylation Diagnosis Prognosis 

Notes

Acknowledgments

This work was supported by the National Natural Science Foundation of China (No. 81000984), the Six Talent Peaks Project of the Jiangsu Province (2011-WS066), and the Social Undertakings of Science and Technology Innovation and Demonstration Project of Nantong City (HS2014042).

Compliance with ethical standards

All procedures were approved by the Human Research Ethics Committee at the Affiliated Hospital of Nantong University, and written informed consent was obtained from all patients before obtaining the serum and/or tumor samples.

Conflicts of interest

None

References

  1. 1.
    May M. Statistics: attacking an epidemic. Nature. 2014;509:S50–51.CrossRefPubMedGoogle Scholar
  2. 2.
    Feng L, Yao C, Li P, Feng Y, Wang F, Liu YF, Guo YB, Mao QS, Xue WJ. Low expression of fibulin-1 correlates with unfavorable prognosis in gastric cancer. Tumour Biol 2016Google Scholar
  3. 3.
    Pourhoseingholi MA, Vahedi M, Baghestani AR. Burden of gastrointestinal cancer in Asia; an overview. Gastroenterol Hepatol Bed Bench. 2015;8:19–27.PubMedPubMedCentralGoogle Scholar
  4. 4.
    De Angelis R, Sant M, Coleman MP, Francisci S, Baili P, Pierannunzio D, et al. Cancer survival in Europe 1999–2007 by country and age: results of EUROCARE-5—a population-based study. Lancet Oncol. 2014;15:23–34.CrossRefPubMedGoogle Scholar
  5. 5.
    Ilson DH. Angiogenesis in gastric cancer: hitting the target? Lancet. 2014;383:4–6.CrossRefPubMedGoogle Scholar
  6. 6.
    Oba K, Paoletti X, Alberts S, Bang YJ, Benedetti J, Bleiberg H, Catalano P, Lordick F, Michiels S, Morita S, Ohashi Y, Pignon JP, Rougier P, Sasako M, Sakamoto J, Sargent D, Shitara K, Cutsem EV, Buyse M, Burzykowski T, group G: Disease-free survival as a surrogate for overall survival in adjuvant trials of gastric cancer: a meta-analysis. J Natl Cancer Inst 2013;105:1600–1607Google Scholar
  7. 7.
    Liu BL, Cheng JX, Zhang W, Zhang X, Wang R, Lin H, et al. Quantitative detection of multiple gene promoter hypermethylation in tumor tissue, serum, and cerebrospinal fluid predicts prognosis of malignant gliomas. Neuro Oncol. 2010;12:540–8.CrossRefPubMedPubMedCentralGoogle Scholar
  8. 8.
    Lo Nigro C, Wang H, McHugh A, Lattanzio L, Matin R, Harwood C, et al. Methylated tissue factor pathway inhibitor 2 (TFPI2) DNA in serum is a biomarker of metastatic melanoma. J Investig Dermatol. 2013;133:1278–85.CrossRefPubMedGoogle Scholar
  9. 9.
    Hashad D, Sorour A, Ghazal A, Talaat I. Free circulating tumor DNA as a diagnostic marker for breast cancer. J Clin Lab Anal. 2012;26:467–72.CrossRefPubMedGoogle Scholar
  10. 10.
    Morgan SR, Whiteley J, Donald E, Smith J, Eisenberg MT, Kallam E, et al. Comparison of KRAS mutation assessment in tumor DNA and circulating free DNA in plasma and serum samples. Clin Med Insights Pathol. 2012;5:15–22.CrossRefPubMedPubMedCentralGoogle Scholar
  11. 11.
    Wang YC, Yu ZH, Liu C, Xu LZ, Yu W, Lu J, et al. Detection of RASSF1A promoter hypermethylation in serum from gastric and colorectal adenocarcinoma patients. World J Gastroenterol. 2008;14:3074–80.CrossRefPubMedPubMedCentralGoogle Scholar
  12. 12.
    Zanetti-Dallenbach R, Wight E, Fan AX, Lapaire O, Hahn S, Holzgreve W, et al. Positive correlation of cell-free DNA in plasma/serum in patients with malignant and benign breast disease. Anticancer Res. 2008;28:921–5.PubMedGoogle Scholar
  13. 13.
    Sherwood V, Manbodh R, Sheppard C, Chalmers AD. RASSF7 is a member of a new family of RAS association domain-containing proteins and is required for completing mitosis. Mol Biol Cell. 2008;19:1772–82.CrossRefPubMedPubMedCentralGoogle Scholar
  14. 14.
    Hesson LB, Dunwell TL, Cooper WN, Catchpoole D, Brini AT, Chiaramonte R, et al. The novel RASSF6 and RASSF10 candidate tumour suppressor genes are frequently epigenetically inactivated in childhood leukaemias. Mol Cancer. 2009;8:42.CrossRefPubMedPubMedCentralGoogle Scholar
  15. 15.
    Hill VK, Underhill-Day N, Krex D, Robel K, Sangan CB, Summersgill HR, et al. Epigenetic inactivation of the RASSF10 candidate tumor suppressor gene is a frequent and an early event in gliomagenesis. Oncogene. 2011;30:978–89.CrossRefPubMedGoogle Scholar
  16. 16.
    Dansranjavin T, Wagenlehner F, Gattenloehner S, Steger K, Weidner W, Dammann R, et al. Epigenetic down regulation of RASSF10 and its possible clinical implication in prostate carcinoma. Prostate. 2012;72:1550–8.CrossRefPubMedGoogle Scholar
  17. 17.
    Wei Z, Chen X, Chen J, Wang W, Xu X, Cai Q. RASSF10 is epigenetically silenced and functions as a tumor suppressor in gastric cancer. Biochem Biophys Res Commun. 2013;432:632–7.CrossRefPubMedGoogle Scholar
  18. 18.
    Schagdarsurengin U, Richter AM, Wohler C, Dammann RH. Frequent epigenetic inactivation of RASSF10 in thyroid cancer. Epigenetics. 2009;4:571–6.CrossRefPubMedGoogle Scholar
  19. 19.
    Helmbold P, Richter AM, Walesch S, Skorokhod A, Marsch W, Enk A, et al. RASSF10 promoter hypermethylation is frequent in malignant melanoma of the skin but uncommon in nevus cell nevi. J Investig Dermatol. 2012;132:687–94.CrossRefPubMedGoogle Scholar
  20. 20.
    Li Z, Chang X, Dai D, Deng P, Sun Q. RASSF10 is an epigenetically silenced tumor suppressor in gastric cancer. Oncol Rep. 2014;31:1661–8.PubMedGoogle Scholar
  21. 21.
    Guo J, Yang Y, Yang Y, Linghu E, Zhan Q, Brock MV, et al. RASSF10 suppresses colorectal cancer growth by activating P53 signaling and sensitizes colorectal cancer cell to docetaxel. Oncotarget. 2015;6:4202–13.CrossRefPubMedPubMedCentralGoogle Scholar
  22. 22.
    Deng J, Liang H, Ying G, Li H, Xie X, Yu J, et al. Methylation of ras association domain protein 10 (RASSF10) promoter negative association with the survival of gastric cancer. Am J Cancer Res. 2014;4:916–23.PubMedPubMedCentralGoogle Scholar
  23. 23.
    Li X, Liang Q, Liu W, Zhang N, Xu L, Zhang X, Zhang J, Sung JJ, Yu J. Ras association domain family member 10 suppresses gastric cancer growth by cooperating with GSTP1 to regulate JNK/c-Jun/AP-1 pathway. Oncogene 2015Google Scholar
  24. 24.
    Kim ST, Jang HL, Lee J, Park SH, Park YS, Lim HY, et al. Clinical significance of IGFBP-3 methylation in patients with early stage gastric cancer. Transl Oncol. 2015;8:288–94.CrossRefPubMedPubMedCentralGoogle Scholar
  25. 25.
    Zang ZJ, Cutcutache I, Poon SL, Zhang SL, McPherson JR, Tao J, et al. Exome sequencing of gastric adenocarcinoma identifies recurrent somatic mutations in cell adhesion and chromatin remodeling genes. Nat Genet. 2012;44:570–4.CrossRefPubMedGoogle Scholar
  26. 26.
    Calcagno DQ, Gigek CO, Chen ES, Burbano RR, Smith Mde A. DNA and histone methylation in gastric carcinogenesis. World J Gastroenterol. 2013;19:1182–92.CrossRefPubMedPubMedCentralGoogle Scholar
  27. 27.
    Ziogas D, Roukos D. Epigenetics in gastric cancer: challenges for clinical implications. Ann Surg Oncol. 2009;16:2077–8.CrossRefPubMedGoogle Scholar
  28. 28.
    McCabe MT, Brandes JC, Vertino PM. Cancer DNA methylation: molecular mechanisms and clinical implications. Clin Cancer Res. 2009;15:3927–37.CrossRefPubMedPubMedCentralGoogle Scholar
  29. 29.
    Roder DM. The epidemiology of gastric cancer. Gastric Cancer. 2002;5 Suppl 1:5–11.CrossRefPubMedGoogle Scholar
  30. 30.
    Qu Y, Dang S, Hou P. Gene methylation in gastric cancer. Clin Chim Acta. 2013;424:53–65.CrossRefPubMedGoogle Scholar
  31. 31.
    Konturek PC, Konturek SJ, Brzozowski T. Gastric cancer and Helicobacter pylori infection. J Physiol Pharmacol. 2006;57 Suppl 3:51–65.Google Scholar
  32. 32.
    Plummer M, Franceschi S, Vignat J, Forman D, de Martel C. Global burden of gastric cancer attributable to Helicobacter pylori. Int J Cancer. 2015;136:487–90.CrossRefPubMedGoogle Scholar
  33. 33.
    Matsusaka K, Funata S, Fukayama M, Kaneda A. DNA methylation in gastric cancer, related to Helicobacter pylori and Epstein-Barr virus. World J Gastroenterol. 2014;20:3916–26.CrossRefPubMedPubMedCentralGoogle Scholar
  34. 34.
    Wang F, Meng W, Wang B, Qiao L. Helicobacter pylori-induced gastric inflammation and gastric cancer. Cancer Lett. 2014;345:196–202.CrossRefPubMedGoogle Scholar
  35. 35.
    Wang F, Feng Y, Li P, Wang K, Feng L, Liu YF, Huang H, Guo YB, Mao QS, Xue WJ. RASSF10 is an epigenetically inactivated tumor suppressor and independent prognostic factor in hepatocellular carcinoma. Oncotarget 2015Google Scholar
  36. 36.
    Tahara T, Arisawa T. DNA methylation as a molecular biomarker in gastric cancer. Epigenomics. 2015;7:475–86.CrossRefPubMedGoogle Scholar
  37. 37.
    Leung WK, To KF, Chu ES, Chan MW, Bai AH, Ng EK, et al. Potential diagnostic and prognostic values of detecting promoter hypermethylation in the serum of patients with gastric cancer. Br J Cancer. 2005;92:2190–4.CrossRefPubMedPubMedCentralGoogle Scholar
  38. 38.
    Abbaszadegan MR, Moaven O, Sima HR, Ghafarzadegan K, A’Rabi A, Forghani MN, et al. p16 promoter hypermethylation: a useful serum marker for early detection of gastric cancer. World J Gastroenterol. 2008;14:2055–60.CrossRefPubMedPubMedCentralGoogle Scholar
  39. 39.
    Cheung KF, Lam CN, Wu K, Ng EK, Chong WW, Cheng AS, et al. Characterization of the gene structure, functional significance, and clinical application of RNF180, a novel gene in gastric cancer. Cancer. 2012;118:947–59.CrossRefPubMedGoogle Scholar
  40. 40.
    Ikoma H, Ichikawa D, Koike H, Ikoma D, Tani N, Okamoto K, et al. Correlation between serum DNA methylation and prognosis in gastric cancer patients. Anticancer Res. 2006;26:2313–6.PubMedGoogle Scholar
  41. 41.
    Sakakura C, Hamada T, Miyagawa K, Nishio M, Miyashita A, Nagata H, et al. Quantitative analysis of tumor-derived methylated RUNX3 sequences in the serum of gastric cancer patients. Anticancer Res. 2009;29:2619–25.PubMedGoogle Scholar

Copyright information

© International Society of Oncology and BioMarkers (ISOBM) 2016

Authors and Affiliations

  • Wan-Jiang Xue
    • 1
  • Ying Feng
    • 1
  • Fei Wang
    • 1
  • Peng Li
    • 1
  • Yi-Fei Liu
    • 2
  • Yi-Bing Guo
    • 3
  • Zhi-Wei Wang
    • 1
  • Qin-Sheng Mao
    • 1
    • 4
  1. 1.Department of General SurgeryNantong University Affiliated HospitalNantongChina
  2. 2.Department of PathologyNantong University Affiliated HospitalNantongChina
  3. 3.Department of Surgical Comprehensive LaboratoryNantong University Affiliated HospitalNantongChina
  4. 4.Department of Minimally Invasive SurgeryThe Affiliated Hospital of Nantong UniversityNantongChina

Personalised recommendations